Panion & Bf Biotech Inc. (1760.TW)
TWD 81.4
(-1.57%)
TWD 81.4
(-1.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 327.21 Million TWD | -35.16% |
| 2022 | 504.61 Million TWD | 47.1% |
| 2021 | 343.04 Million TWD | 89.05% |
| 2020 | 181.45 Million TWD | -38.8% |
| 2019 | 296.48 Million TWD | 4.0% |
| 2018 | 253.74 Million TWD | 54.22% |
| 2017 | 186.32 Million TWD | 7.5% |
| 2016 | 171.82 Million TWD | 15.33% |
| 2015 | 152.81 Million TWD | 48.42% |
| 2014 | 90.28 Million TWD | 95.09% |
| 2013 | 51.49 Million TWD | 389.86% |
| 2012 | -15.53 Million TWD | -27.91% |
| 2011 | -13.97 Million TWD | -12.63% |
| 2010 | -12.66 Million TWD | -130.58% |
| 2009 | 40.11 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 80.01 Million TWD | -33.99% |
| 2024 Q1 | 119.92 Million TWD | 20.8% |
| 2023 Q4 | 100.35 Million TWD | 28.9% |
| 2023 FY | - TWD | -35.16% |
| 2023 Q1 | 95.63 Million TWD | 301.71% |
| 2023 Q2 | 82.38 Million TWD | -13.86% |
| 2023 Q3 | 77.85 Million TWD | -5.5% |
| 2022 Q1 | 107.58 Million TWD | 68.81% |
| 2022 Q3 | 169.14 Million TWD | -38.56% |
| 2022 Q4 | -47.41 Million TWD | -128.03% |
| 2022 FY | - TWD | 47.1% |
| 2022 Q2 | 275.3 Million TWD | 155.9% |
| 2021 Q3 | 116.42 Million TWD | -12.29% |
| 2021 Q4 | 63.73 Million TWD | -45.26% |
| 2021 FY | - TWD | 89.05% |
| 2021 Q1 | 30.15 Million TWD | -60.97% |
| 2021 Q2 | 132.74 Million TWD | 340.27% |
| 2020 Q4 | 77.24 Million TWD | 96.5% |
| 2020 Q1 | 36 Million TWD | -59.06% |
| 2020 Q3 | 39.31 Million TWD | 36.02% |
| 2020 FY | - TWD | -38.8% |
| 2020 Q2 | 28.9 Million TWD | -19.73% |
| 2019 FY | - TWD | 4.0% |
| 2019 Q4 | 87.94 Million TWD | 67.26% |
| 2019 Q1 | 72.45 Million TWD | -44.15% |
| 2019 Q3 | 52.57 Million TWD | -37.04% |
| 2019 Q2 | 83.51 Million TWD | 15.27% |
| 2018 Q1 | 21.64 Million TWD | -49.42% |
| 2018 FY | - TWD | 54.22% |
| 2018 Q4 | 129.71 Million TWD | 132.24% |
| 2018 Q3 | 55.85 Million TWD | -28.97% |
| 2018 Q2 | 78.63 Million TWD | 263.29% |
| 2017 Q1 | 62.89 Million TWD | -36.41% |
| 2017 Q2 | 31.85 Million TWD | -49.35% |
| 2017 Q3 | 47.31 Million TWD | 48.52% |
| 2017 FY | - TWD | 7.5% |
| 2017 Q4 | 42.79 Million TWD | -9.55% |
| 2016 Q2 | 18.8 Million TWD | 0.0% |
| 2016 Q4 | 98.91 Million TWD | 161.02% |
| 2016 Q3 | 37.89 Million TWD | 101.5% |
| 2016 FY | - TWD | 15.33% |
| 2016 Q1 | 18.8 Million TWD | -66.7% |
| 2015 FY | - TWD | 48.42% |
| 2015 Q4 | 56.48 Million TWD | 0.0% |
| 2015 Q3 | 56.48 Million TWD | 183.52% |
| 2015 Q2 | 19.92 Million TWD | 0.0% |
| 2015 Q1 | 19.92 Million TWD | -24.0% |
| 2014 Q2 | 18.92 Million TWD | 0.0% |
| 2014 FY | - TWD | 95.09% |
| 2014 Q1 | 18.92 Million TWD | 101.18% |
| 2014 Q4 | 26.21 Million TWD | 0.0% |
| 2014 Q3 | 26.21 Million TWD | 38.48% |
| 2013 Q3 | 9.4 Million TWD | 3.07% |
| 2013 Q4 | 9.4 Million TWD | 0.0% |
| 2013 FY | - TWD | 389.86% |
| 2013 Q1 | 9.12 Million TWD | 194.57% |
| 2013 Q2 | 9.12 Million TWD | 0.0% |
| 2012 FY | - TWD | -27.91% |
| 2012 Q3 | -9.65 Million TWD | 0.0% |
| 2012 Q4 | -9.65 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | - TWD | -12.63% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | - TWD | -130.58% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Apex Biotechnology Corp. | 221.06 Million TWD | -48.023% |
| Sinphar Pharmaceutical Co.,Ltd. | 582.94 Million TWD | 43.868% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 473.81 Million TWD | 30.939% |
| GenMont Biotech Incorporation | 71.76 Million TWD | -355.94% |
| Abnova (Taiwan) Corporation | 81.2 Million TWD | -302.934% |
| Adimmune Corporation | -512.42 Million TWD | 163.857% |
| Tanvex BioPharma, Inc. | -1.75 Billion TWD | 118.651% |
| Polaris Group | -1.38 Billion TWD | 123.549% |
| Energenesis Biomedical CO.,LTD. | -244.57 Million TWD | 233.79% |
| UnicoCell Biomed Co., Ltd. | -56.27 Million TWD | 681.454% |
| PELL Bio-Med Technology Co. Ltd. | -353.17 Million TWD | 192.65% |